DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for premature ovarian failure 8 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePremature ovarian failure 8 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for premature ovarian failure 8 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The 2007 review describes premature ovarian failure as a complex disease with multiple autoimmune mechanisms. Animal models show both global immune dysregulation affecting multiple glands and targeted ovarian pathology. In patients, the glycolytic enzyme alpha-enolase is a potential antigenic target, particularly in those with polyglandular involvement, and the ovarian-specific protein Mater, essential for fertility, is also implicated. The review states that autoimmunity may be mediated by T cells targeting zona pellucida proteins or by B cells and antibodies targeting inhibin-alpha. No drug or intervention is tested in this abstract.
The 2010 review notes that premature ovarian failure is a complex disorder with genetic factors playing an important role. It states that the aetiology and pathophysiology are still debated. The review is a summary of inherited factors and does not report any clinical trial or treatment outcome.
The 2024 review states that the etiology and pathogenesis may relate to genetic, immunological, medical, environmental, infectious, psychological and enzyme deficiencies. It lists treatment categories as Western medicine, Chinese medicine, and a combination, at levels including hormone, cellular, surgery and psychological. No specific drug, response rate, survival data, or sample size is reported. The review does not provide evidence for any particular treatment's efficacy.
No abstract reports a clinical trial, a tested drug, or a measurable outcome such as pregnancy rate or hormone restoration. What is missing is any randomised controlled trial, any patient stratification by autoimmune subtype or genetic marker, and any funding for mechanistic studies that could link the proposed autoimmune targets to a specific intervention.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Obstetrics & Gynecology · 2007 · 34 citations
Autoimmunity and premature ovarian failure
AbstractPURPOSE OF REVIEW: The different patterns of autoreactivity that may account for the premature infertility observed in patients with premature ovarian failure are described. RECENT FINDINGS: Animal model studies have detailed fundamental immune dysregulatory patterns that induce ovarian failure in the context of global polyglandular involvement, as well as autoimmune mechanisms that induce ovarian failure in the context of targeted ovarian pathology. Recent studies on premature ovarian failure patients implicate the ubiquitously expressed glycolytic enzyme, alpha-enolase, as a potential antigenic target, particularly in those patients with polyglandular involvement; and the ovarian-specific maternal-effect protein, Mater, whose expression is essential for fertility. SUMMARY: Several fundamentally distinct mechanisms may account for premature ovarian failure, including global immune dysregulation, particularly in patients with polyglandular autoimmunity. Premature ovarian failure may also be due to inflammatory autoimmunity targeted to ovarian-specific germline antigens (e.g., zona pellucida proteins or Mater) or differentiation/regulatory factors (e.g., inhibin-alpha). Moreover, the ovarian autoimmunity may be mediated by T cells (e.g., those targeting zona pellucida proteins) or B cells/antibodies (e.g., those targeting inhibin-alpha). Thus premature ovarian failure appears to be a complex disease entity with multiple underlying etiopathogenic contributions including the possibility of several distinctly different autoimmune mechanisms.
Chromosomal abnormalities in women with premature ovarian failure
AbstractPremature ovarian failure is a complex disorder that results in the early loss of ovarian function; however this disease must be separated from early menopause because these patients can sporadically ovulate and in literature are described pregnancies. The aetiology and the patho-physiology of premature ovarian failure are still matter of debate, but is commonly accepted that genetic factors play an important role. This review is aimed to present an overview of known inherited factor implied in the pathogenesis of this disorder to help physician in the counselling of affected pregnant women.
Journal of Clinical and Nursing Research · 2024 · 0 citations · open access
Recent Research Progress in Premature Ovarian Failure
AbstractPremature ovarian failure refers to ovarian function failure in women before the age of 40 years due to follicular depletion or follicular dysfunction resulting in abnormal hormone levels. The etiology and pathogenesis of premature ovarian failure may be related to genetic, immunological, medical, environmental, infectious, psychological and enzyme deficiencies. The treatment involves Western medicine, Chinese medicine, and a combination of Chinese and Western medicine, and the treatment level includes hormone level, cellular level, surgery and psychological aspect. This paper would like to review the progress of the etiology, pathogenesis and treatment of premature ovarian failure in recent years.
Hormone Therapy in Women with Premature Ovarian Failure: Is Transdermal Safer Than Oral?
AbstractConventional treatment for premature ovarian failure consists of oral contraceptives (OCs) or menopausal hormone therapy. In an open-label, randomized, crossover trial, investigators in Scotland compared the effects of an OC (30 µg of ethinyl estradiol and 1.5 mg of norethindrone daily for 21 days, followed by 7 hormone-free days) with those of transdermal estrogen (0.1-mg estradiol patch, week 1; 0.15-mg patch, weeks 2 and 3; no estrogen, week 4) plus cyclical vaginal …
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
